Mariner LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 115,415 shares of the company’s stock after selling 11,723 shares during the quarter. Mariner LLC’s holdings in Johnson & Johnson were worth $14,790,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Goodman Financial Corp purchased a new stake in Johnson & Johnson in the fourth quarter worth about $104,000. Stelac Advisory Services LLC purchased a new stake in Johnson & Johnson in the fourth quarter worth about $108,000. Princeton Capital Management LLC purchased a new stake in Johnson & Johnson in the first quarter worth about $141,000. Smart Portfolios LLC purchased a new stake in Johnson & Johnson in the first quarter worth about $150,000. Finally, Signition LP purchased a new stake in Johnson & Johnson in the first quarter worth about $204,000. Institutional investors own 71.53% of the company’s stock.
A number of equities research analysts have weighed in on JNJ shares. ValuEngine cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Tuesday, May 22nd. Goldman Sachs Group upgraded shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a report on Thursday, July 12th. TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b” rating in a report on Friday, May 18th. Sanford C. Bernstein started coverage on shares of Johnson & Johnson in a report on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 price objective on the stock. Finally, Credit Suisse Group set a $151.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Friday, July 13th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $142.34.
In other news, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the transaction, the chief operating officer now owns 59,124 shares in the company, valued at $7,969,915.20. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.22% of the company’s stock.
Shares of NYSE JNJ opened at $136.87 on Friday. The company has a market capitalization of $364.50 billion, a PE ratio of 17.42, a PEG ratio of 2.07 and a beta of 0.69. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.04. The firm had revenue of $20.83 billion for the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.83 earnings per share. research analysts anticipate that Johnson & Johnson will post 8.14 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 11th. Stockholders of record on Tuesday, August 28th will be paid a $0.90 dividend. The ex-dividend date is Monday, August 27th. This represents a $3.60 annualized dividend and a dividend yield of 2.63%. Johnson & Johnson’s dividend payout ratio is presently 49.32%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: What is a Leveraged Buyout (LBO)?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.